This recorded webcast focuses on the 10 business issues outlined in PwC's Top health industry issues of 2016 report, including merger mania, the new money managers, new databases improving patient care and consumer health, and more.
In this recorded webcast focusing on emerging accounting developments affecting not-for-profit organizations, we will cover recent FASB standard setting developments that have occurred since our October webcast. As always, the focus is on not-for-profit organizations that apply FASB standards, with an emphasis on healthcare and higher education institutions.
HRI’s annual Top health industry issues report highlights the forces that are expected to have the most impact on the industry in the coming year, with a glance back at key trends from the past decade.
In this alert, we provide a pharmaceutical and life sciences perspective to the FASB Income tax projects update.
The PwC Rx Marketplace Quarterly features a wide range of financial reporting developments, accounting and tax developments, regulatory updates and general industry trends impacting the pharmaceutical and life sciences industry.
The first segment of this recorded webcast features a tax policy update, including the political and economic factors driving US and global tax policy in 2016 and beyond. The second segment provides highlights of tax accounting matters pharmaceutical and life sciences companies should consider when preparing their annual income tax provision.
To help registrants gain insight into the SEC’s current areas of interest, PwC analyzed comments released by the SEC staff to domestic large accelerated, accelerated and non-accelerated registrants within the healthcare provider industry.
In this webcast, our tax specialists discuss key areas impacting healthcare providers including academic medical centers, universities, and other tax-exempt organizations.
PwC's publication provides a comprehensive analysis of recent SEC staff comments and disclosures to assist you in understanding the key trends relevant to companies in the pharmaceutical and life sciences sector.
After a record second quarter, the pharmaceutical and life sciences (PLS) industry continued to demonstrate a healthy deal value and volume in the third quarter. Closed deal volume increased from the prior quarter to 59 from 46 transactions, with deal value decreasing to $67.6 billion from $72.2 billion. Announced and pending transactions continued to shine at $118.9 billion in deal value and 110 transactions.